Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBITDA Margin (2017 - 2025)

UroGen Pharma's EBITDA Margin history spans 9 years, with the latest figure at 69.69% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 8375.0% year-over-year to 69.69%; the TTM value through Dec 2025 reached 139.84%, up 46.0%, while the annual FY2025 figure was 139.84%, 46.0% up from the prior year.
  • EBITDA Margin reached 69.69% in Q4 2025 per URGN's latest filing, up from 121.28% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 69.69% in Q4 2025 to a low of 348.2% in Q1 2021.
  • Average EBITDA Margin over 5 years is 168.68%, with a median of 160.88% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: skyrocketed 810449bps in 2021, then tumbled -5341bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 176.09% in 2021, then grew by 10bps to 159.3% in 2022, then surged by 31bps to 109.94% in 2023, then crashed by -40bps to 153.44% in 2024, then skyrocketed by 55bps to 69.69% in 2025.
  • Per Business Quant, the three most recent readings for URGN's EBITDA Margin are 69.69% (Q4 2025), 121.28% (Q3 2025), and 206.27% (Q2 2025).